A Boston startup that analyzes blood samples to guide cancer treatment decisions just closed an $83.5 million financing round, and Pittsburgh’s UPMC Enterprises is among the new investors backing the precision medicine company.
Read More from Bizjournals.com Feed (2025-02-17 17:26:56)